消息面，小核酸药物治疗乙肝取得突破性数据，未来小核酸药物在乙肝领域的推进值得期待。受消息面提振，单日涨跌幅20%的科创创新药 ETF（589720） 涨超2.5%。资金持续布局，连续5日迎资金净流入。 关注20cm标的科创创新药 ETF（589720），跟踪指数"924行情"以来跑赢港股创新药 展望后市，创新药行业在出海持续突破、政策红利不断释放以及中国创新药企业研发实力稳步提升的多重驱动下，正迎来广阔的发展空间，具备较好的投资 机会，可以关注相关20cm标的科创创新药 ETF国泰（589720）。 科创创新药ETF国泰（589720）聚焦科创板创新药企业，跟踪汇聚30家代表性优质公司的上证科创板创新药指数，以高成长biotech为主，产品20%涨跌幅限 制使其更贴合板块波动。 2025年小核酸迎来首个爆发周期 小核酸药物治疗乙肝取得突破性数据，在近日举办的2025年美国肝病研究协会（AASLD2025）年会上浩博医药披露了两项反义寡核苷酸（ASO）药物AHB- 137针对慢性乙型肝炎患者治疗结束后24周的2期随访数据，从现有数据来看，AHB-137有望成为潜在最佳的乙肝小核酸药物，未来小核酸药物在乙肝领域的 ...

中信建投指出，医保谈判稳步推进，创新产品有望惠及更多患者，2025年新增药品中国产占比超70%。 集采更注重质量导向和临床价值，降价幅度趋稳。ADC、GLP-1、双抗等技术领域持续突破，国内企业 全球竞争力提升。政策端集采优化和商业保险目录为创新药支付提供增量空间。 科创创新药ETF国泰（589720）聚焦科创板创新药企业，跟踪汇聚30家代表性优质公司的上证科创板创 新药指数，以高成长biotech为主，产品20%涨跌幅限制使其更贴合板块波动。从业绩表现来看，2024年 9月24日至2025年10月31日市场反弹期间，科创新药/恒生港股通创新药指数涨幅分别为 143.70%/135.34%，科创新药指数或有助于在市场风险偏好回升时更好地分享科创板的弹性。 （文章来源：每日经济新闻） ...

相关机构表示，近些年，国内企业创新药研发成果持续涌现，外资企业也逐步改变依赖过专利期原研 药'轻松获利'的模式。数据显示，"十四五"期间，我国共批准创新药210个、创新医疗器械269个，且均 保持加速增长态势。目前，我国生物医药市场规模跃居全球第二，在研创新药约占全球的30%。2025年 上半年，创新药对外授权总金额接近660亿美元，全球市场对中国创新药的认可度正在不断提升。"十五 五"规划建议明确部署"优化药品集采"，国家医保局后续将加强评估、总结经验、补齐短板，持续推动 集采工作规范化、制度化、常态化开展。 国内企业创新药研发成果持续涌现，科创创新药ETF国泰（589720）回调超3%，资金逢低布局，近20 日净流入近2亿元。 科创创新药ETF国泰（589720）聚焦科创板创新药企业，跟踪汇聚30家代表性优质公司的上证科创板创 新药指数，以高成长biotech为主，产品20%涨跌幅限制使其更贴合板块波动。从业绩表现来看，2024年 9月24日至2025年9月30日市场反弹期间，科创新药/恒生港股通创新药指数涨幅分别为 117.04%/109.62%，科创新药指数或有助于在市场风险偏好回升时更好地分享科创板 ...

Market Overview - The A-share market showed weakness today, influenced by a drop of over 2% in the Nasdaq, with the Shanghai Composite Index closing at 3990.49 points, down 0.97% [1] - The Shenzhen Component fell by 1.93%, and the ChiNext Index dropped by 2.82%, with more than 3300 stocks declining [1] - Trading volume in both markets was below 2 trillion yuan, indicating a lack of activity [1] Sector Performance - Only sectors such as oil and petrochemicals, real estate, banking, and pharmaceuticals showed resilience, while other sectors, particularly AI, communications, and chips, experienced significant declines [1] - The recent fluctuations in the global market have led to a cautious sentiment among domestic investors, raising concerns about whether A-shares will follow the downward trend of overseas markets [1][2] Economic Indicators - Key credit indicators like social financing have shown mediocre performance, indicating a lag in the recovery of confidence in the real economy [5] - In October, new RMB loans amounted to 220 billion yuan, a decrease of 280 billion yuan year-on-year, while social financing increased by 815 billion yuan, down 597 billion yuan year-on-year [5] Investment Sentiment - The current market sentiment is influenced by short-term risk preferences and trading emotions, with a belief that domestic market logic will eventually prevail [2][4] - The ongoing economic stabilization and supportive policies are expected to provide a foundation for valuation levels, suggesting that recent pullbacks could present buying opportunities [4] AI and Innovation Sector - The AI sector faces uncertainties regarding revenue contributions and high capital expenditures, with many companies still in the investment phase and struggling to achieve stable profitability [6] - The introduction of AI in drug discovery and development is seen as a significant opportunity, with potential for increased efficiency and reduced costs in the pharmaceutical industry [12][13] Gold Market - The gold market has shown strong performance compared to equity markets, with recent geopolitical tensions and economic uncertainties driving demand for gold as a safe-haven asset [15][16] - The long-term outlook for gold remains positive due to systemic risks, including inflation and geopolitical tensions, which are expected to support gold prices [16]

行业板块几乎全线上扬，能源金属、电池、化肥行业、贵金属、电源设备、非金属材料、有色金属、化 学原料、化学制品、小金属板块涨幅居前，仅铁路公路、银行、电力行业逆市翻绿。 今日开盘后，沪指强势冲高，午后继续上行，创下2015年7月以来新高。尽管盘中出现一定回落，但尾 盘阶段指数再度拉升。自大盘站上4000点以来，整体展现出较强的韧性，虽偶有波动，但市场重心不断 上移。临近2025年年底，日历效应有望再度显现。国际货币秩序重构逻辑持续强化，AI革命进入应用 关键阶段，新能源电池领域迎来重要创新突破，我国创新产业逐步实现业绩兑现，预计将继续为中国资 产表现提供支撑。 锂电产业链全线爆发，带动新能源板块今日集体上涨。新能源车ETF（159806）收涨6.20%，创业板新 能源ETF国泰（159387）收涨4.78%。 A股三大指数今日集体走强，沪指再度刷新十年新高。截止收盘，沪指涨0.73%，收报4029.50点；深证 成指涨1.78%，收报13476.52点；创业板指涨2.55%，收报3201.75点。沪深两市成交额达到20420亿，较 昨日放量969亿。 来源：Wind 消息面上，三生制药临床进度持续超预期，昨日辉 ...

Market Overview - A-shares opened slightly lower and fluctuated before stabilizing, with the Shanghai Composite Index closing at 3997.56 points, down 0.25% [1] - The Shenzhen Component Index fell by 0.36%, and the ChiNext Index decreased by 0.51%, with over 3100 stocks declining [1] - The trading volume in both markets was approximately 2 trillion, slightly lower than the previous day [1] Sector Performance - Software and innovative drug sectors showed weaker performance, while chemical and photovoltaic sectors gained due to rising raw material prices and anti-involution policies [1] - The innovative drug ETF from Guotai (589720) has seen continuous inflows, totaling over 200 million in the last five trading days [7] Investment Sentiment - Concerns about the "AI bubble" and its potential impact on A-shares have emerged, with investors questioning whether market corrections present opportunities or traps [1] - Despite fluctuations in the external market, the domestic market's valuation logic remains strong, with a clear investment outlook emerging [2] Future Outlook - The bull market is expected to continue, with new leading sectors likely to emerge during the rotation process [5] - The innovative drug sector is anticipated to see both profit and valuation increases, driven by positive industry news and AI's role in drug development [9][11] - The coal sector is experiencing a rebound, with recent price increases and inventory reductions providing support for near-term performance [15][17] Policy and Economic Factors - Ongoing policy developments are expected to improve macroeconomic expectations, supporting coal prices from both supply and demand sides [17] - The introduction of AI in drug development is likely to enhance efficiency and reduce costs, further boosting the innovative drug sector [12][13]

Group 1 - The industry leaders are increasing their investment in AI applications for healthcare, with the number of registered models and algorithms expected to reach 101 by the end of 2024, showing a gradual upward trend [1] - Major hospitals in China, particularly top-tier hospitals, are accelerating the deployment and application of AI large models, leading to the development of specialized models for specific diseases, indicating a deepening phase of AI application in healthcare [1] - The Guotai ETF (589720) focuses on innovative drug companies in the STAR Market, tracking 30 representative high-quality companies, and has shown strong performance since the "924 market" period, outperforming the Hang Seng Hong Kong Stock Connect innovative drug index [1] Group 2 - During the market rebound from September 24, 2024, to September 30, 2025, the STAR Market innovative drug index increased by 117.04%, while the Hang Seng Hong Kong Stock Connect innovative drug index rose by 109.62%, suggesting that the STAR Market index may better capture the sector's volatility when market risk appetite improves [1]

Group 1 - The core viewpoint is that China's biopharmaceutical sector is experiencing significant growth in research and development capabilities, with a notable increase in the number of new drug approvals [1] - In 2023, the National Medical Products Administration (NMPA) approved 87 drugs, including 5 domestically innovative drugs, indicating a strengthening of China's drug development landscape [1] - The number of external licensing transactions has increased from 15 in 2019 to 33 in 2023, reflecting growing international confidence in Chinese biotechnology products [1] Group 2 - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies listed on the STAR Market, tracking an index of 30 representative high-quality companies [1] - Since the "924 market" period, the STAR Market innovative drug index has outperformed the Hang Seng Hong Kong Stock Connect innovative drug index, with respective gains of 117.04% and 109.62% during the market rebound from September 24, 2024, to September 30, 2025 [1] - The STAR Market innovative drug index may provide better exposure to the resilience of the STAR Market when market risk appetite increases [1]

Market Overview - A-shares experienced a slight decline influenced by weak performance in U.S. tech stocks, with the Shanghai Composite Index closing at 3954.79 points, down 0.81% [1] - The market saw a total of 3759 stocks rise and 1548 stocks fall, with trading volume around 2.35 trillion, indicating a gradual recovery in market activity [1] - The market initially surged past the 4000-point mark but faced selling pressure, leading to a retreat [2] Sector Performance - Innovative drugs, software, and media sectors led the gains, while previously strong sectors like telecommunications, semiconductor equipment, and AI-related concepts faced corrections [1] - The biotech sector showed strong performance, with the Kweichow Moutai Innovation Drug ETF rising over 7% [9] Investment Strategy - Investors are advised to adopt a "rational offensive" strategy, focusing on low-position stocks with high elasticity for potential gains [2][4] - The current market environment suggests that while short-term pressure at the 4000-point level remains, long-term bullish sentiment is building due to the accumulation of wealth effects [4] Industry Insights - The innovative drug sector is entering a critical phase of performance realization, with significant funding expected to accelerate commercialization processes [11] - AI technology is increasingly being integrated into drug development, enhancing efficiency and reducing costs in the early stages of research [12] Economic Context - The U.S. economic outlook remains uncertain, with concerns over "stagflation" and regional banking risks impacting market sentiment [13] - Geopolitical tensions in regions like the Middle East and Ukraine are contributing to heightened market volatility and investor caution [14] Long-term Outlook - The long-term bullish outlook for A-shares is supported by the relative strength of China's comprehensive national power compared to the U.S. [4] - The potential for further valuation increases in the innovative drug sector is anticipated as industry policies evolve and AI capabilities expand [13]

Core Viewpoint - The market is shifting its focus from short-term BD to the long-term pipeline value of innovative domestic drugs, particularly those with source innovation capabilities and FIC/BIC product matrices, following data releases from the ESMO conference [1] Group 1: Market Trends - The upcoming National Medical Insurance negotiation in November will determine the speed of new drug hospital adoption, while the December commercial insurance innovation drug catalog may address the issue of high-priced drugs entering hospitals, complementing the medical insurance system [1] - The JP Morgan Healthcare Conference in January is expected to attract global attention, further highlighting the innovative drug sector [1] Group 2: Investment Opportunities - The Guotai Innovation Drug ETF (589720) focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking a representative index of 30 high-quality companies, primarily in high-growth biotech [1] - Since the "924 market" last year, the Sci-Tech Innovation Drug Index has outperformed the Hang Seng Hong Kong Stock Connect Innovation Drug Index, with respective gains of 117.04% and 109.62% during the market rebound period from September 24, 2024, to September 30, 2025 [1] - The Sci-Tech Innovation Drug Index may provide better exposure to the resilience of the Sci-Tech Innovation Board when market risk appetite increases [1]